Apogee Therapeutics, Inc. Common Stock annual gross profit for fiscal TTM was -$1 million, an increase of 0.0% from -$1 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit | ($1M) | ($1M) | $0M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Gross Profit | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More APGE metrics: Revenue · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All APGE financial statements → Interactive APGE charts →
About TickerBase · Data methodology & sources · Privacy · Terms